Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Vaxcyte Inc has a consensus price target of $126.25 based on the ratings of 10 analysts. The high is $163 issued by Mizuho on September 10, 2024. The low is $60 issued by SVB Leerink on December 16, 2022. The 3 most-recent analyst ratings were released by Mizuho, B of A Securities, and Leerink Partners on September 10, 2024, September 4, 2024, and September 3, 2024, respectively. With an average price target of $152 between Mizuho, B of A Securities, and Leerink Partners, there's an implied 31.97% upside for Vaxcyte Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Vaxcyte (NASDAQ:PCVX) was reported by Mizuho on September 10, 2024. The analyst firm set a price target for $163.00 expecting PCVX to rise to within 12 months (a possible 41.52% upside). 17 analyst firms have reported ratings in the last year.
The latest analyst rating for Vaxcyte (NASDAQ:PCVX) was provided by Mizuho, and Vaxcyte maintained their outperform rating.
There is no last upgrade for Vaxcyte
There is no last downgrade for Vaxcyte.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vaxcyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vaxcyte was filed on September 10, 2024 so you should expect the next rating to be made available sometime around September 10, 2025.
While ratings are subjective and will change, the latest Vaxcyte (PCVX) rating was a maintained with a price target of $113.00 to $163.00. The current price Vaxcyte (PCVX) is trading at is $115.18, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.